| Healthcare utilization and physical functioning in older adults in the United States Y Cheng, AJ Goodin, M Pahor, T Manini, JD Brown Journal of the American Geriatrics Society 68 (2), 266-271, 2020 | 49 | 2020 |
| The impact of naloxone coprescribing mandates on opioid-involved overdose deaths M Sohn, C Delcher, JC Talbert, Y Cheng, Y Xu, ED Jadhav, PR Freeman American journal of preventive medicine 64 (4), 483-491, 2023 | 7 | 2023 |
| Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors Y Cheng, L Anthony, C Delcher, DC Moga, A Chauhan, B Huang, ... The Oncologist 28 (6), 479-485, 2023 | 3 | 2023 |
| Medicaid expansion and access to naloxone in metropolitan and nonmetropolitan areas Y Cheng, PR Freeman, E Slade, M Sohn, JC Talbert, C Delcher The Journal of Rural Health 39 (2), 347-354, 2023 | 2 | 2023 |
| Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review Z Chen, Y Cheng, D DeRemer, V Diaby Expert Review of Pharmacoeconomics & Outcomes Research 21 (5), 923-941, 2021 | 2 | 2021 |
| Prevalence and Predictors of Burnout Among Resident Family Physicians S Doe, A Coutinho, A Weidner, Y Cheng, K Sanders, AW Bazemore, ... Family Medicine 56 (3), 148, 2024 | 1 | 2024 |
| Variation in practice patterns of early-and later-career family physicians PJ Carek, Y Cheng, AW Bazemore, LE Peterson The Journal of the American Board of Family Medicine 37 (1), 35-42, 2024 | 1 | 2024 |
| Predictors of Pancreatitis Among Patients with Inflammatory Bowel Disease Treated with Vedolizumab: Observation from a Large Global Safety Database JF Wernicke, T Verstak, T Zhang, W Spalding, L Lee, Y Cheng, A Ademi Drugs-Real World Outcomes 10 (4), 557-564, 2023 | | 2023 |
| EPH239 Treatment Pattern and Drug-Drug Interactions in Patients with Metastatic Castration Resistant Prostate Cancer Y Cheng, C Delcher, D Moga, B Huang, V Adams Value in Health 26 (6), S206, 2023 | | 2023 |
| P625 Predictors of pancreatitis among patients with inflammatory bowel disease (IBD) treated with vedolizumab (VDZ): Observation from a large global safety database J Wernicke, T Verstak, T Zhang, W Spalding, L Lee, Y Cheng, A Ademi Journal of Crohn's and Colitis 16 (Supplement_1), i548-i549, 2022 | | 2022 |
| The impact of naloxone co-prescribing mandates on mortality: Does opioid type matter? M Sohn, C Delcher, Y Cheng, J Talbert, Y Xu, E Jadhav, PR Freeman APHA 2021 Annual Meeting and Expo, 2021 | | 2021 |
| Drug utilization and prescribing pattern of concomitant use of enzalutamide and anticoagulation Y Cheng, V Adams, C Delcher, DC Moga, B Huang PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 30, 200-200, 2021 | | 2021 |
| Real-world utilization of octreotide immediate releasing use with octreotide long-acting releasing Y Cheng, V Adams, LB Anthony, C Delcher, DC Moga, A Chauhan, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 30, 320-321, 2021 | | 2021 |
| Rural variation of the impact of medicaid expansion on naloxone access Y Cheng, P Freeman, M Sohn, E Shin, C Delcher PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 29, 276-276, 2020 | | 2020 |
| COST-EFFECTIVENESS OF IMMUNOTHERAPY AGENTS FOR HEMATOLOGIC MALIGNANCIES: A SYSTEMATIC REVIEW Z Chen, Y Cheng, K Diaby, D DeRemer ISPOR Europe 2019, 2019 | | 2019 |
| The Impact of Naloxone Coprescribing Mandates on Opioid-Involved Overdose Deaths M Sohn, C Delcher, JC Talbert, Y Cheng, Y Xu, ED Jadhav, PR Freeman | | |
| Medicare-Paid Naloxone: Trends in Non-Metropolitan and Metropolitan Areas C Delcher, Y Cheng, M Sohn, JC Talbert, PR Freeman | | |
